A leading pharmaceutical industry group is seeking to score a speedy victory in its resurrected legal challenge to the Biden administration’s drug price negotiation program.
The Pharmaceutical Research and Manufacturers of America, along with co-plaintiffs the National Infusion Center Association and the Global Colon Cancer Association, is urging the US District Court for the Western District of Texas to agree with its claims that the Medicare Drug Price Negotiation Program is unconstitutional.
“If allowed to stand, the Drug Pricing Program will dramatically slow innovation, reduce the availability of new medicines, and undermine public health, causing grave harm to patients, pharmaceutical ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.